Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887717 | 0.92 | MAPT (0.70) | MAPTGAAMEN1NPC1ALDH1A1 | |
| SCHEMBL4884824 | 0.86 | MAPT (0.79) | MAPTGAAMEN1NPC1ALDH1A1 | |
| SCHEMBL12540244 | 0.84 | NPC1 (0.57) | MAPTGAAMEN1NPC1ALDH1A1 | |
| SCHEMBL12540663 | 0.84 | MAPT (0.58) | MAPTGAAMEN1NPC1ALDH1A1 | |
| SCHEMBL12540111 | 0.84 | GAA (0.58) | MAPTGAAMEN1NPC1ALDH1A1 | |
| SCHEMBL14941545 | 0.82 | MAPT (0.49) | MAPTGAAMEN1NPC1ALDH1A1 | |
| SCHEMBL12541011 | 0.81 | GAA (0.63) | MAPTGAAMEN1NPC1ALDH1A1 | |
| SCHEMBL12541017 | 0.80 | GAA (0.66) | MAPTGAAMEN1NPC1ALDH1A1 | |
| SCHEMBL12542070 | 0.78 | HTT (0.61) | MAPTGAAMEN1NPC1ALDH1A1 | |
| SCHEMBL14950938 | 0.78 | MAPT (0.49) | MAPTGAAMEN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245147-A1 | INHIBITORS OF THAPSIGARGIN-INDUCED CELL DEATH | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-09-27 | — | — | US | disclosed |
| US-20080293699-A1 | Inhibitors of thapsigargin-induced cell death | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245147-A1 | INHIBITORS OF THAPSIGARGIN-INDUCED CELL DEATH | HSPA5, HSP90B1, ATP2A1 | MAPT 2245/4885GAA 239/4885MEN1 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.